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Key Points
• NOTCH2 activation confers a
marked increase in BCR
responsiveness by cGVHD
patient B cells that associates
with increased BLNK.
• ATRA increases the





B-cell receptor (BCR)-activated B cells contribute to pathogenesis in chronic graft-
versus-host disease (cGVHD), a condition manifested by both B-cell autoreactivity and
immune deficiency. We hypothesized that constitutive BCR activation precluded
functional B-cell maturation in cGVHD. To address this, we examined BCR-NOTCH2
synergy because NOTCH has been shown to increase BCR responsiveness in normal
mouse B cells. We conducted ex vivo activation and signaling assays of 30 primary
samples from hematopoietic stem cell transplantation patients with and without cGVHD.
Consistentwithamolecular linkbetweenpathways,we found thatBCR-NOTCHactivation
significantly increased the proximal BCR adapter protein BLNK. BCR-NOTCH activation
also enabled persistent NOTCH2 surface expression, suggesting a positive feedback
loop. Specific NOTCH2 blockade eliminated NOTCH-BCR activation and significantly
altered NOTCH downstream targets and B-cell maturation/effector molecules. Examina-
tion of the molecular underpinnings of this “NOTCH2-BCR axis” in cGVHD revealed
imbalanced expression of the transcription factors IRF4 and IRF8, each critical to B-cell
differentiation and fate. All-trans retinoic acid (ATRA) increased IRF4 expression,
restored the IRF4-to-IRF8 ratio, abrogated BCR-NOTCH hyperactivation, and reduced NOTCH2 expression in cGVHD B cells without
compromising viability. ATRA-treated cGVHD B cells had elevated TLR9 and PAX5, but not BLIMP1 (a gene-expression pattern
associated with mature follicular B cells) and also attained increased cytosine guanine dinucleotide responsiveness. Together, we
reveal a mechanistic link between NOTCH2 activation and robust BCR responses to otherwise suboptimal amounts of surrogate
antigen. Our findings suggest that peripheral B cells in cGVHD patients can be pharmacologically directed from hyperactivation
toward maturity. (Blood. 2017;130(19):2131-2145)
Introduction
Themost devastating long-term side effect of allogeneic hematopoietic
stem cell transplantation (HCT) is chronic graft-versus-host disease
(cGVHD).1,2 Incited by recipient alloantigens, cGVHD evolves into a
recalcitrant autoreactive and immunocompromised state.3,4 Aberrantly
activated T and B cells are found in patients.5-9 Specific roles for
these cells in cGVHD pathogenesis have been substantiated in
mouse models, leading to clinical trials.2,10,11 Despite these advances,
inadequate understanding of immune mechanisms in human cGVHD
hinders our ability to prevent and treat cGVHD without further
compromising immunity.
Both cGVHD patients and mice have increased hyperactivated
B cells and allo- and autoantibody titers.5,6,8,12 After HCT, a unique
combination of extrinsic factors including alloantigens and cytokines
results in high potential for altered B- and T-cell homeostasis.13,14
High B-cell activating factor (BAFF) is found in patients and has
been shown to associate with activation and survival of aberrantly
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activated B cells.5,15 Compared with B cells from non-cGVHD patients,
cGVHD B cells are activated via extracellular signal-regulated kinase
(ERK) and AKT.5 Total numbers of CD271B cells remain persistently
low after HCT.16 cGVHD B cells are both paradoxically responsive to
recipient antigens17-19 and dysfunctional. Rare CD271 cells circulating
in cGVHD patients constitutively produce immunoglobulin G (IgG),
but are not typical “memory” B cells.5 cGVHD patients are notoriously
unable to combat encapsulated organisms or mount proper IgG recall
responses.20-22 Increased immature transitional-like CD21Lo B cells
and a paucity of IgD1CD271“memory”Bcells associatewith increased
infection rates in cGVHD.23,24 Thus, constitutive B-cell activation in
cGVHD may preclude functional B-cell maturation.
In cGVHD patients, heightened BCR responses and greater
BAFF dependence for survival are functional properties shared
with marginal zone (MZ) B cells.5,6,25-27 Activation through the
NOTCH2 receptor28,29 and the level of BCR ligation are pivotal for
MZ vs follicular B-cell fate in mice.30,31 Notch ligands augment
normal mouse BCR or CD40 responses to relatively high amounts of
surrogate antigen or ligand.32 T-cell alloreactivity after HCT is driven
by NOTCH ligand in secondary lymphoid organs,33 but whether
B cells after HCT are aberrantly activated via the NOTCH pathway
remains unknown. Given the well-defined role of NOTCH2 in the fate
of immature-transitional B cells in both mice29 and humans,28 we
hypothesized that NOTCH2 is aberrantly activated in cGVHD.
Using a human B-cell assay system, we discovered that B-cell
hyperactivation in cGVHD is rooted in synergistic NOTCH2-BCR
signaling. We also found that alterations in IRF4 and IRF8 are
associated with NOTCH2 expression and hyperresponsiveness.
Capitalizing on the pharmacological effect of all-trans retinoic acid
(ATRA) on IRF4 expression levels, we showed a mechanistic link
between IRF4 and NOTCH2 that enabled reversal of the abnormal
response of cGVHD B cells. NOTCH2-BCR axis blockade with
ATRAalso led to expressionofTLR9 andPAX5, indicatingmovement
toward a B-cell maturation pathway.34-36
Methods
Patient and healthy donor samples
Viably frozen peripheral blood mononuclear cells (PBMCs) from HCT patients
were obtained with institutional review board protocols from Duke University,
the National Cancer Institute (NIH), and the Dana-Farber Cancer Institute.
Patient characteristics are described in Table 1 and supplemental Table 1
(available on the Blood Web site). Healthy donor PBMCs were obtained from
Gulf Coast Regional Blood Center.
In vitro assays
B cells were purified using Human B Cell Isolation kits (Miltenyi Biotec).
For NOTCH ligand stimulation, B cells were incubated on OP9-DL1 cells
(kindly provided by Yuan Zhuang, Duke University, Durham, NC). B cells
were B-cell receptor (BCR)-stimulated with anti-human IgM antibody
(Ab) used as surrogate antigen plus or minus pan-NOTCH inhibition with
10mMN-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
(DAPT). To specifically inhibit NOTCH2 activation, the anti-NOTCH2
monoclonal Ab (mAb)37 was used at 1 mg/mL vs 1 mg/mL mouse IgG2a
anti-ragweed mAb37 isotype control. We used 100 nM ATRA vs dimethyl
sulfoxide (DMSO) as vehicle control, added 30 minutes before anti-IgM.
Flow cytometry
All Abs are listed in supplemental Methods. For intracellular flow cytometry,
B cells were first stained for surface antigens and for live/dead cells before
fixation and permeabilization.
Quantitative PCR
B cells were cultured for 24 hours plus or minus anti-IgM at the indicated doses,
plus or minus ATRA, before harvest, total RNA isolation, and complementary
DNA (cDNA) generation. Quantitative PCR (qPCR) was performed with the
Applied Biosystems StepOne Plus System (Thermo Fisher Scientific) and Bio-
Rad iTaq Universal SYBR Green Supermix.
NanoString and RNA-Seq analyses
Anti-N2 or isotype control mAbs (1 mg/mL) were added to B cells on OP9-
DL1 feeder cell monolayers. After 30 minutes, anti-IgM was added.
Twenty-four hours later, B cells were purified from the feeder cells via
human CD19 microbeads (Miltenyi Biotec). B-cell total RNA was isolated
by the RNeasy Plus kit. RNA-sequencing (RNA-Seq) data sets lacked
detectable expression of genes characteristic of other leukocyte or precursor
lineages, demonstrating high B-cell purity. NanoString gene-expression
profiling of RNA samples was assessed via the nCounter Pan-Cancer Pathways
Panel representing known NOTCH pathway genes. For RNA-Seq, RNA was
subjected to Illumina HiSeq 125-bp paired-end sequencing.
High-throughput sequencing of IGHV genes
cDNAwas amplifiedwith the Invitrogen Superscript Platinum III TaqHi-Fidelity
RT-PCR kit. Primers for framework region 2 (FR2) of the immunoglobulin
heavy-chain variable region (IGHV) genes and a common IGH joining (J) gene,
were used for amplification.38
Further details are available in the supplemental Methods.





n 5 17 P
Median age (range), y 51 (29-73) 49 (22-69) .57
Sex, females, no. (%) 5 (42) 5 (29) .71
Median time after transplant (range), mo 43 (12-81) 45 (12-114) .71
Conditioning regimen (%) .71
Myeloablative 6 (46) 10 (59)
Nonmyeloablative 7 (54) 7 (41)
Source of graft (%) 1
Peripheral blood 10 (77) 13 (76)
Bone marrow 3 (23) 4 (24)
HLA matching (%) .72
Matched, unrelated 7 (54) 8 (47)
Matched, related 6 (46) 7 (41)
Mismatched 0 (0) 2 (12)
Immunosuppressive treatment (%) ,.0001
Prednisone ,0.5 mg/kg 1 (8) 10 (59)
MMF 0 (0) 1 (6)
Tacrolimus 1 (8) 7 (41)
Rapamycin 0 (0) 1 (6)
Initial disease (%) .41
AML/AML from MDS 4 (31) 5 (29)
ALL 0 (0) 2 (12)
CML 0 (0) 1 (6)
CLL 2 (15) 1 (6)
MDS 3 (23) 3 (18)
NHL 1 (8) 2 (12)
MM 1 (8) 0 (0)
AA 2 (15) 0 (0)
Other 0 (0) 3 (18)
All patients were consented, all samples were obtained, and all studies were
approved under the institutional review board protocols of Duke University, the
National Institutes of Health, and the Dana-Farber Cancer Institute. Statistical
comparisons between groups were performed using the Fisher exact test.
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid
leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS,
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Figure 1. NOTCH2 ligation heightens ex vivo
active cGVHD B-cell responses to minimal
BCR engagement by surrogate antigen.
B cells were magnetically purified to.95% from
viably frozen PBMCs from HCT patients who at
the time of sample collection had active cGVHD
(Active; n 5 9) or no cGVHD (No; n 5 6). After
plating B cells onto OP9 stromal cell mono-
layers or OP9-DL1 cells that express the
NOTCH ligand DLL1, cultures were either
treated with the g-secretase inhibitor DAPT
(10 mM in DMSO) to block Notch activation, or
with DMSO alone. After 30 minutes, agonistic
anti-IgM Ab was added to the appropriate wells
at a concentration of 0.625 mg/mL. The cells
were cultured for 72 hours, harvested, and flow
cytometry analysis performed to assess Ki-67
expression. (A) Representative flow cytometry
histograms for Ki-67 expression are shown for
healthy donor (Healthy), no cGVHD (No), or
active cGVHD (Active) donor B cells cultured in
the presence of 0.625 mg/mL anti-IgM and
plated on OP9 parental cells (top panels) or
OP9-DL1 cells (bottom panels). The effect of
DAPT treatment on active cGVHD B cells is
also shown (right panels). (B-C) Frequency of
Ki-671 B cells for all patients assessed in each
group where the B cells were stimulated with
0.625 mg/mL anti-IgM (B) or were not stimu-
lated through the BCR (C). P values were
determined using a nonpaired Student t test for
intergroup comparisons, and paired Student
t test for same group comparisons. (D) Repre-
sentative flow cytometry histograms showing
BLNK expression as assessed by intracellular
flow cytometry in B cells from active cGVHD
patients stimulated as described for panel A,
with plating on OP9 cells or OP9-DL1 cells. (E)
Median fluorescence intensity (MFI) expression
for BLNK in B cells from n 5 4 active cGVHD
patients stimulated as described for panel A
and cultured on OP9-DL1 cells. In some
cultures, DAPT (10 mM) was added to inhibit
NOTCH activation, or R406 (0.1 mM) was
added to inhibit SYK. DMSO alone used as
the vehicle control in parallel. P values were
determined using a paired Student t test.
Results
Increased NOTCH activation heightens BCR responsiveness of
cGVHD patient B cells
Thirty samples from HCT patients with or without active cGVHD
were studied (Table 1; supplemental Table 1). At the time of sample
acquisition, patients were on #0.5 mg/kg of steroids, were .12
months post-HCT, and had not received B-cell depletion or modu-
lating therapies within 3 years.
To examine the effect of NOTCH ligand activation on BCR-
stimulated B cells from cGVHD patients, we first tested whether
NOTCH activation decreased the response threshold to low-dose
surrogate antigen (anti-IgM) in our ex vivo assays. B cells from active
cGVHD patients responded to 80-fold less anti-IgM than is required
for optimal BCR activationwhen used alone.6Without NOTCH ligand
(Figure 1A top panel), a small percentage of active cGVHD patient
B cells became BCR-activated, whereas only about 1% of healthy or
no cGVHD B cells became activated. With NOTCH ligand DLL1
(Figure 1A bottom panel), a higher proportion of B cells from active
cGVHD patients was activated compared with B cells from healthy
donors or patients without cGVHD. This response was blocked with
g-secretase inhibitor DAPT, which blocks proteolytic activation of
NOTCH (Figure 1A right top and bottompanels). As in Figure 1B, after
DLL1 and anti-IgM exposure, a significantly greater proportion of
B cells from active cGVHD patients was activated vs B cells from
patients without cGVHD. DAPT eliminated both high-level activation
of cGVHDBcells andmodest activation inBcells frompatientswithout
cGVHD, confirming the requirement for NOTCH (Figure 1B). Re-
markably, even without ex vivo BCR stimulation, NOTCH activation
induced modest and significant activation of cGVHDB cells compared
with B cells from patients without cGVHD (Figure 1C), an effect also
abolished by DAPT-mediated NOTCH blockade. These data suggest
that constitutive BCR activation in vivo primes cGVHD B cells to
respond through NOTCH.
We previously found that BLNK expression increases after BCR
activationof healthyBcells and is constitutively increased inBcells from
patients with active cGVHD.6 BLNK protein increased in a NOTCH-
BCR–dependent manner in active cGVHD B cells (Figure 1D-E). Pan-
NOTCH (with DAPT) or BCR blockade (with Syk inhibitor, R406/
fostamatinib) each reduced BLNK to similar levels of unstimulated
B cells (Figure 1E). Thus, data suggest that the BCR pathway in active
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Figure 2. Hyperactivation of active cGVHD patient
B cells to NOTCH ligand and anti-IgM is NOTCH2-
dependent. (A-B) Anti-N2 mAb (N2) or ragweed isotype
control mAb (Iso) were diluted in medium and added to
96-well plates containing OP9-DL1 feeder cell mono-
layers to achieve a final concentration of 1 mg/mL.
B cells purified from viably frozen PBMCs of active
cGVHD patients (n 5 6) were then added to the plates.
Following an initial culture period of 30 minutes, agonistic
anti-IgM Ab was added to the appropriate wells at a
final concentration of 0.625 mg/mL. The cells were
cultured for 72 hours, harvested, and flow cytometry
analysis performed to assess Ki-67 expression (A),
and relative cell size by forward scatter (FSC) (B).
P values were determined using a paired Student t test
(*P , .05; **P , .01). (C) NOTCH-BCR stimulation with
or without specific NOTCH2 blockade with anti-N2, as
described in panels A and B. The cells were cultured for
24 hours, the B cells purified away from the feeder cells
using magnetic microbeads, and RNA isolated. B-cell
RNA was then subjected in NanoString gene-expression
profiling to assess differences in NOTCH pathway-
regulated genes between groups. Data points represent
NanoString nCounter target count number of individual
samples for each gene, graphed on a relative scale.
Statistical analysis comparing the anti-N2– and isotype
control–treated groups was performed using a paired,































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































NOTCH-BCR activation of B cells from cGVHD patients relies
on NOTCH2
NOTCH2 is the dominant NOTCH receptor expressed by B cells
and is essential for MZ B-cell development.28,29 Because DAPT is
a pan-NOTCH inhibitor, we tested whether NOTCH2 is specifi-
cally responsible for the heightened activation of cGVHD B cells.
For this, we used an antagonistic anti-NOTCH2 mAb that specifically
inhibits NOTCH2 activation by DLL1.37 This mAb, called “anti-N2”
herein (also known as anti–negative regulatory region 2 [anti-NRR2]37),
binds and stabilizes theNOTCH2NRR,preventing activation.As shown
in Figure 2A, anti-N2 effectively suppressed cGVHD B-cell responses
to NOTCH-BCR stimulation. Anti-N2 also significantly blocked the
modest response to NOTCH ligand alone. Anti-N2 conferred signifi-
cantly decreased cell size after NOTCH2-BCR stimulation, suggesting
prevention of B-cell blast development (Figure 2B). NOTCH blockade
did not cause B-cell death because B-cell numbers were not different
after anti-N2 compared with isotype control mAbs or DAPT (data not
shown). To qualitatively assess how anti-N2 affected cGVHD B-cell
activation, we analyzed genes associated with NOTCH using a
NanoString expression-profiling platform. As shown in Figure 2C,
anti-N2 significantly and selectively reduced expression of HES1,
HDAC2, and MFNG, whereas other genes in the NOTCH pathway
remained unaffected. Together, these data demonstrate that NOTCH-
BCR hyperresponsiveness in cGVHD B cells requires NOTCH2.
Downstream effectors of NOTCH2 in B cells remain largely
unknown39 and have not been studied in cGVHD. Anti-N2 blocks
proteolysis and release of theNOTCH2 intracellular domain, effectively
blocking NOTCH2-induced transcription.37 We thus used RNA-Seq
to identify additional gene alterations in BCR-NOTCH–stimulated
cGVHDBcells caused byNOTCH2blockade via paired comparison of
4 active cGVHD patient B-cell samples treated with anti-N2 vs isotype
controlmAb.A total of 12 880 geneswere expressed above background
in the RNA-Seq analysis. Of these, NOTCH2 blockade led to the
differential expression of 65 genes with an adjusted P value of ,.05
(Benjamini-Hochberg method calculation to account for multiple com-
parisons40; Table 2), and 1478 genes having an overall P value of,.05
(supplemental Table 2). Strikingly, NOTCH2 blockade on cGVHD
B cells was not globally suppressive, as both increased and decreased
gene-expression changes occurred (42% and 58%, respectively;
Table 2). Kyoto Encyclopedia of Genes and Genomes pathways
analysis of the RNA-Seq data showed that the cell-cycle pathway
and multiple metabolic pathways were downregulated by NOTCH2
blockade (supplemental Figure 1A; supplemental Table 3). Other
important pathways were upregulated, including theMAPK and BCR
pathways (supplemental Figure 1B; supplemental Table 3). Impor-
tantly, apoptosis pathways were not altered by NOTCH2 blockade
(supplemental Table 3), further suggesting no negative impact on B-cell
survival. GeneOntology (GO): Biological Process (www.geneontology.
org) classification of the 65 genes in Table 2 identified important medi-
ators of immune responses, includingBCRsignaling,NOTCHsignaling,
and cell-cycle progression (Table 3). Notably, genes encoding proteins
critical to MZ-like B-cell development and function, CR2 (CD21) and
FCRL4 (IRTA1), were significantly decreased by NOTCH2 blockade.
By contrast, anti-N2 enhanced genes of known importance for follicu-
lar B cells, including DUSP1, TNFSF12, and FOS. Putative NOTCH
pathway genes identified in the RNA-Seq analysis were in agreement
with the NanoString findings, except that LFNG reached a significant
P value by RNA-Seq only (supplemental Table 4). Altered MFNG
and LFNG expression is intriguing because these FRINGE glycosyl-
transferases modify the extracellular domains of NOTCH receptors,
altering their affinity for NOTCH ligands, including NOTCH2-DLL1
pairing during MZ B-cell development.41 Our results reveal the im-
portance of NOTCH2 activation in cGVHD B cells, and implicate
candidate genes essential to this process.
NOTCH-BCR activation leads to persistent surface expression
of NOTCH2 on cGVHD B cells
We next examined whether BCR activation affected NOTCH2
expression in cGVHD. Freshly isolated B cells from active cGVHD
patients, patients without cGVHD, and healthy donors all expressed
similar surface NOTCH2 (supplemental Figure 2). With continuous
NOTCH ligand and anti-IgM stimulation, however, B cells from active
cGVHD patients maintained significantly higher NOTCH2 surface
expression (Figure3A-B), similar to expression foundwithoutNOTCH
ligand (no DLL1; data not shown). NOTCH2 expression on active
cGVHD B cells was significantly reduced with DAPT (Figure 3A-B).
On healthy B cells, NOTCH2was expressed at increasing levels on the
surface with increasing doses of anti-IgM (Figure 3C left panel),
whereas in the presence of NOTCH ligand, NOTCH2 surface expres-
sion was not maintained (Figure 3C right panel). Thus, persistent
NOTCH2expression by active cGVHDBcells likely reflects a positive
feedback-activation loop dependent on both NOTCH2 and the BCR.
Skewing of the BCR repertoire could potentially cause enhanced
surrogate antigen sensitivity. To address this, we used high-throughput
sequencing of the IGHV complementarity-determining region 3 (CDR3)
repertoire invariousBCR-activatedCD271andCD272B-cell subsets.14
This limited analysis revealed similar usage frequency of the majority






HES4 Hes family BHLH transcription factor 4
MMP9* Matrix metalloproteinase 9
DUSP1* Dual-specificity phosphatase 1
TNFSF12* Tumor necrosis factor superfamily member 12;
TWEAK
BIRC5† Baculoviral IAP repeat containing 5
IL6R Interleukin 6 receptor; CD126 antigen
BCR signaling FOS*† Cellular oncogene C-Fos
CR2 Complement component 3d receptor 2; CD21
antigen
FCRL4 Fc receptor-like 4; IRTA1
PSTPIP1* Proline-serine-threonine phosphatase-interacting
protein 1
CDC25A† Cell division cycle 25A
Cell cycle FOS*† Cellular oncogene C-Fos
DTL Denticleless E3 ubiquitin protein ligase homolog
CDC6 Cell division cycle 6
SLC19A1 Solute carrier family 19 member 1
BIRC5† Baculoviral IAP repeat containing 5
CDC25A† Cell division cycle 25A
MYBL2 MYB proto-oncogene–like 2
TTLL12 Tubulin tyrosine ligase–like 12
SKA3 Spindle and kinetochore–associated complex
subunit 3
ORC6 Origin recognition complex subunit 6
UBE2C Ubiquitin-conjugating enzyme E2 C
BHLH, basic helix loop helix; IAP, inhibitor of apoptosis.
Genes shown in bold are downregulated by NOTCH2 blockade.
*Genes upregulated by NOTCH2 blockade.
†Genes categorized into .1 signaling pathway.
Table 3. GO: Biological process classification of genes within the 
NOTCH, BCR, and cell-cycle–signaling cascades in cGVHD B cells 
after NOTCH2 blockade
well as between each cell subset examined (supplemental Figure 3).
Consistent with this, there were no differences in cGVHD B-cell subset
CDR3 Shannon entropy or mutational scores (data not shown). Thus, a
major skewing of the BCR repertoire unlikely explains NOTCH2-BCR
hyperresponsiveness of cGVHD B cells.
IRF4 and IRF8 are altered in cGVHD B cells, especially after
BCR engagement
Increased BCR signaling across various populations of B cells in
cGVHD6 suggested that additional intrinsic molecular alterations
underlie their hyperactivated state. Because inducible deletion of the
transcription factor IRF4 in theB-cell lineage inmice leads to enhanced
NOTCH2 expression,42 we examined IRF4 expression in cGVHD
B cells. It has been hypothesized that BCR-signaling strength regu-
lates IRF4 levels.43 After BCR stimulation, IRF4 transcripts were
significantly lower in B cells from active cGVHD patients relative to
B cells from patients with no cGVHD (Figure 4A), consistent with our
previous finding in CD271 B cells.6 Interestingly, at low-dose anti-
IgM, B cells from patients without cGVHD had significantly increased
IRF4 expression compared with healthy B cells. Regardless, the sig-
nificant IRF4 decrease in B cells from HCT patients with cGVHD
suggests a molecular link between this pivotal transcription factor and
NOTCH2.
IRF8 attenuates BCR signaling in a fashion that antagonizes IRF4.
A critical balance between IRF4 and IRF8 determines mouse B-cell
fate after antigen encounter in vivo.44 Thus, we also assessed IRF8
compared with IRF4 transcripts. Remarkably, IRF8 expression was
significantly increased in unstimulated B cells from both active
cGVHD and no cGVHD patient groups relative to healthy donors
(Figure 4B). This indicates a fundamental change in IRF8 expression
after HCT. Because IRF8 overexpression is associated with B-cell
anergy,45 this enhancement in IRF8may contribute to B-cell tolerance
in the HCT setting. UponBCR engagement at both low and high doses
of anti-IgM, IRF8 levels were significantly reduced in each of the
3 groups relative to unstimulated B cells (P, .05 for active cGVHD;
P, .01 for no cGVHD, healthy donors). Importantly, IRF8 transcripts
remained significantly higher in B cells from active cGVHD patients
comparedwith healthy donors at each anti-IgM concentration, whereas
IRF8 transcripts remained significantly higher in B cells from patients
without cGVHD comparedwith healthy donors only at the higher dose
(Figure 4B). We found the IRF4-to-IRF8 ratio in resting B cells was
significantly lower for bothHCTpatient groups comparedwith healthy
donors (Figure 4C). Remarkably, only B cells from active cGVHD
patients maintained a significantly reduced median IRF4-to-IRF8 ratio
after stimulationwith low or higher dose surrogate antigen (Figure 4C).
Thus, because functional humoral immune responses are known to rely
on an intricate balance in the relative expression of IRF4 and IRF8
during various stages of B-cell development and activation,43,44,46-48
our findings suggest that these transcription factors may represent a
pivotal B-cell maturation checkpoint after HCT.
The vitamin A metabolite ATRA increases IRF4 expression in
normal human B cells stimulated with cytosine guanine dinucleotide
(CpG).49 Thus, we tested whether ATRA enhances the blunted IRF4
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Figure 3. NOTCH2 expression is maintained on
active cGVHD B cells in the presence of NOTCH
ligand and BCR stimulation. (A-B) B cells were purified
from viably frozen PBMCs of HCT patients with active
cGVHD (Active, n 5 4) or no cGVHD (No, n 5 4) and
plated in medium onto OP9-DL1 feeder cell monolayers.
In some wells, the g-secretase inhibitor DAPT was added
for a final concentration of 10 mM, with DMSO alone used
as the vehicle control in parallel. Following an initial
culture period of 30 minutes, agonistic anti-IgM Ab was
then added to the appropriate wells at a concentration
of 0.625 mg/mL. The cells were cultured for 72 hours,
harvested, and flow cytometry analysis performed to
assess NOTCH2 surface expression on CD191 B cells.
(A) Representative histogram overlay showing relative
NOTCH2 expression between patient groups and acti-
vation conditions (as indicated). (B) MFI values for all
patients assessed under conditions of anti-IgM stimula-
tion, either without or with DAPT. (C) B cells were purified
from viably frozen PBMCs from healthy donors and
then plated onto monolayers of parental OP9 cells or
OP9-DL1 cells, with various concentrations of anti-IgM
Ab (micrograms per milliliter, indicated by numbers in the
OP9 histogram overlay). Following a culture period of
72 hours, the cells were harvested and analysis of NOTCH2
expression on CD191 cells was performed by flow
cytometry. In panel B, P values were determined using
a nonpaired Student t test for Active vs No comparison,
and a paired Student t test for Active (no DAPT) vs
Active (DAPT) comparison. *P , .05.
cGVHD B cells. ATRA treatment of cGVHD B cells during BCR
activation significantly increased IRF4 levels relative to vehicle (Figure
4D left panel). Although IRF8 transcripts were not significantly al-
tered byATRA (Figure 4Dmiddle panel), the effect of ATRAon IRF4
expression conferred a significant increase in the IRF4-to-IRF8 ratio
(Figure 4D right panel). To confirm that ATRA also affected IRF4 and
IRF8 at the protein level, even in the presence of NOTCH ligand, we
performed intracellular staining and flow cytometry analysis. IRF4
protein levels increased with ATRA treatment above vehicle control
(Figure 4E), in the presence or absence of BCR stimulation. Strikingly,
ATRA treatment significantly reduced IRF8 protein levels with
BCR stimulation (Figure 4E), demonstrating that IRF8 loss can
also contribute to altered IRF4-to-IRF8 ratios in cGVHD B cells at
the protein level.
ATRA alters the genetic maturation program of cGVHD B cells
and restores CpG responsiveness
Foreign antigen-responsive, mature follicular B cells have a gene













































































































































Figure 4. Altered IRF4 and IRF8 gene expression in
B cells from active cGVHD patients, with normal-
ization by ATRA. B cells from HCT patients with
active cGVHD vs no cGVHD (n 5 6), or from healthy
donors (n 5 6) were cultured in medium alone, or with
low-dose (0.625 mg/mL) or high-dose (5 mg/mL)
concentrations of anti-IgM for 24 hours. The B cells
were then harvested, total RNA isolated, and real-time
qPCR analysis performed to assess the abundance of
IRF4 and IRF8 transcripts. The relative expression
level shown for each gene is normalized to the median
value for healthy donors with no anti-IgM stimulation,
represented as a value of 1. (A) IRF4 and (B) IRF8
mRNA levels in each of the 3 sample groups with and
without BCR stimulation. (C) Normalized IRF4 and
IRF8 mRNA expressed as the ratio of IRF4 to that of
IRF8 transcripts (IRF4-to-IRF8). P values were de-
termined using a nonpaired Student t test (*P , .05;
**P , .01). (D) B cells from HCT patients with active
cGVHD (n 5 6) were cultured with ATRA (0.1 mM) or
vehicle alone, followed 30 minutes later by the addition
of 0.625 mg/mL anti-IgM. Following a 24-hour culture
period, the B cells were then harvested, total RNA
isolated, and real-time qPCR analysis performed to
determine relative IRF4 and IRF8 expression, and the
IRF4-to-IRF8 ratio, as described for panels B and C.
(E) B cells from HCT patients with active cGVHD
(n 5 4-6) were plated onto OP9-DL1 monolayers in the
presence of ATRA (0.1 mM) or vehicle alone. Following
an initial culture period of 30 minutes, agonistic anti-
IgM Ab was then added to the appropriate wells at a
final concentration of 0.625 mg/mL. The cells were
cultured for 24 hours, harvested, and intracellular
staining with flow cytometry analysis performed to
assess IRF4 and IRF8 levels. For each protein, data
represent the ratio of ATRA-treated B cells over
vehicle-treated B cells, with the dashed line included
for reference to a value of 1.0.
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Figure 5. ATRA treatment of B cells from active cGVHD patients enhances genes involved in B-cell maturation. (A) B cells from active cGVHD patients (n 5 4) were
treated with ATRA (0.1 mM) or vehicle alone for 24 hours. The B cells were harvested, total RNA isolated, and real-time qPCR analysis performed to assess the expression
levels of genes of interest. P values were determined using a paired Student t test (*P , .05; **P , .01). (B-C) Purified B cells from active cGVHD patients were plated in
medium in the presence of ATRA (0.1 mM) or DMSO vehicle control. Following an initial culture period of 30 minutes, CpG (1 mg/mL) or anti-IgM Ab (0.625 mg/mL) were added
alone or in combination. The cells were cultured for 72 hours, harvested, and flow cytometry analysis performed to assess Ki-67 and CD19 expression (B), as well as relative
cell size by FSC (C). In panel B, the large gates with numbers outside indicate the frequency of Ki-671 B cells, and the small gates (arrows) with numbers inside represent the












































































































































































































Figure 6. ATRA suppresses NOTCH2-BCR hyperresponsiveness of B cells from active cGVHD patients. (A-D) B cells from HCT patients with active cGVHD (n 5 6)
were plated in medium on monolayers of OP9-DL1 feeder cells and exposed to ATRA (0.1 mM) or vehicle alone. Following an initial culture period of 30 minutes, agonistic anti-
IgM Ab was then added to the appropriate wells at a final concentration of 0.625 mg/mL. The cells were cultured for 72 hours, harvested, and flow cytometry analysis
performed to assess B-cell Ki-67 expression (A), FSC as a measure of relative cell size (B), cell-surface NOTCH2 expression (C), and number of live cells (D). (E-F) B cells
from HCT patients with active cGVHD (n 5 4) were plated in medium on monolayers of OP9-DL1 feeder cells and exposed to ATRA (0.1 mM), vehicle alone, anti-N2 mAb, or
isotype control mAb. Following an initial culture period of 30 minutes, agonistic anti-IgM Ab was then added to the appropriate wells at a final concentration of 0.625 mg/mL.
The cells were cultured for 72 hours, harvested, and flow cytometry analysis performed to assess B-cell surface proteins (E) and intracellular ERK1/2 protein phosphorylation (F).
(E) Panel i shows representative dot plots from 1 patient for the treatments indicated; panel ii shows the frequency of CD381IgD2 B cells from all 4 patients under the indicated
culture conditions. (F) Panel i shows representative histograms from 1 patient for the treatments indicated; panel ii shows phospho-ERK MFI levels in B cells from all 4 patients
under the indicated culture conditions. P values were determined using a paired Student t test. n.s., not significant.
TLR9.50 TLR9 is upregulated in normal memory B cells that are
primed for recall immune responses.51 Because ATRA enhances
responsiveness to CpG stimulation of normal human B cells,49,52
and accelerates mature splenic B-cell expansion after vaccination
in normalmice,53we examined howATRAaffects purified, otherwise
unmanipulated, cGVHD patient B cells. We found that along with
IRF4, PAX5 and TLR9 expression were both significantly increased
by ATRA (Figure 5A). There was also a notable increase in XBP1,
but BLIMP1 expression was unchanged by ATRA, pointing away
from a plasma cell differentiation program. These data reveal that
cGVHD patient B cells have potential functional “plasticity” that may
be alterable in vivo.
Having found that ATRA induced TLR9 in cGVHD B cells, we
investigated whether this effect was associated with an augmented
response to CpG. As shown in Figure 5B, the frequency of B cells with
a plasmablast-like phenotype (Ki-671CD19lowFSChigh) induced by
CpG stimulation alone, or by CpG plus anti-IgM, was sixfold greater
with the addition of ATRA. Notably, this ATRA-induced plasmablast-
like phenotype was not accompanied by additional changes in overall
cell size (Figure 5C).Thesefindings indicate apotential to restoreB-cell
function because plasmablast-like cells from patients with cGVHD
have known marked attenuation of CpG-induced signaling compared
with cells from patients without cGVHD.54
ATRA attenuates BCR-NOTCH2 hyperresponsiveness in
cGVHD B cells
IRF4 exerts a suppressive effect on NOTCH signaling in B cells.42
Thus, we examined whether the enhancement of IRF4 by ATRA
culminated in the suppression of cGVHD B-cell hyperresponsiveness
to NOTCH2-BCR stimulation. ATRA treatment resulted in almost
complete suppression of cGVHD B-cell activation by NOTCH2-BCR
stimulation (Figure 6A), along with a reduction in B-cell size
(Figure 6B). The modest activation induced by NOTCH ligand
without the addition of anti-IgM was also significantly reduced by
ATRA (Figure 6A). These data reveal that ATRA potently reverses
the NOTCH2 hyperresponsiveness of cGVHD B cells established
in vivo. Because NOTCH2 expression was maintained on the
surface of active cGVHDB cells during NOTCH2-BCR engagement
(Figure 2A), we investigated whether ATRA affected this process.
Surface NOTCH2 indeed decreased with ATRA (Figure 6C), similar
to the decrease seen when SYK inhibitor R406 blocks BCR signaling
(Figure 6C). Importantly, ATRA treatment did not reduce overall
B-cell viability in these assays (Figure 6D). Instead,ATRAsuppressed
the expansion of a “post-germinal center”CD381IgD2B-cell subset14
(Figure 6Ei-ii). ATRA, as well as anti-N2, also reduced low-level IgM
production after NOTCH2-BCR stimulation (supplemental Figure 4).
ERK1/2 MAPK phosphorylation is necessary for BCR signaling,
but is transient, subsiding within hours of BCR ligation.55,56 ERK1/2
phosphorylation remaineddetectable in cGVHDBcells culturedwithout
anti-IgM, but was reduced in the presence of anti-IgM (Figure 6Fi-ii).
ATRA did not alter this reduction in ERK1/2 phosphorylation,
suggesting it affects the BCR pathway further downstream. Thus,
ATRA blocks NOTCH2 expression and B-cell hyperactivation,
while affording functional responsiveness in pathways.
Discussion
cGVHD has become the most important long-term sequela facing
cancer survivors of allogeneic HCT, and disease mechanisms are
emerging.57 Having demonstrated a role for BCR-activated cells in
the pathophysiology of cGVHD,6,7,12 we now show that NOTCH2
activation is pivotal for aberrant BCR activation in this disease.
Our study begins to elucidate potentially targetable molecular under-
pinnings of B-cell pathology in cGVHD.
After HCT, B cells are constantly exposed to alloantigens. In
cGVHD, potentially pathologic B-cells are promoted to survive through
constitutive signaling via BCR and BAFF-associated pathways.5-7 We
now demonstrate that cGVHD B cells have remarkable sensitivity to
limiting amounts of BCR ligand when NOTCH2 is also activated
(Figures 1-3). Our data show that NOTCH2 is a potent costimula-
tor of aberrant BCR responses in cGVHD. Importantly, alloantigen
appears to prime cGVHD patient B cells in vivo to receive NOTCH
signals. Even without ex vivo BCR stimulation, NOTCH activation
was significantly increased in cGVHD B cells (Figure 1C). BLNK
was also increased in cGVHD B cells following NOTCH-BCR
Table 4. NOTCH-associated pathway gene expression as assessed
in the RNA-Seq analysis of cGVHD B cells after NOTCH2 blockade
Gene ↑ or ↓ log2 fold change P Adjusted P
Rank
(of 12 880)
HES4 ↓ 22.97 2.8 3 10217 1.8 3 10213 2
HES1 ↓ 21.10 3.8 3 1024 .062 80
LFNG ↑ 0.660 .001 .105 133
HDAC2 ↓ 20.541 .014 .321 543
MFNG ↓ 20.525 .016 .339 622
EP300 — 0.667 .061 .454 1 737
MAML2 — 0.552 .119 .510 2 997
NOTCH2 — 0.371 .165 .550 3 867
DTX2 — 0.300 .262 .622 5 430
HDAC1 — 20.101 .595 .828 9 259
DTX1 — 0.030 .926 .976 12 209
DTX4 — 0.026 .933 .979 12 269
cGVHD B cells after NOTCH2 blockade from the experiment described in Table
2. P values and adjusted P values are indicated. The numerical rank for each gene of
all 12 880 genes expressed above background is also indicated, based on the
adjusted P value score.














Potentially Pathological B Cell
Quiescent
Poised for Functional Maturity
Figure 7. Model for a NOTCH2-BCR axis in the generation of pathogenic B cells
in cGVHD. (A) Reduced activation threshold response to antigen and to NOTCH
ligand. High BAFF levels in the cGVHD setting leads to the preferential survival of
B cells with MZ-like properties. These B cells are driven by an abnormally low ratio
of IRF4 to IRF8, and are dependent on NOTCH2 activation of target genes.
BCR-NOTCH2 synergy in these B cells leads to pathogenic Allo-Ab production.
(B) ATRA exposure normalizes the phenotype of cGVHD B cells by increasing the
ratio of IRF4 to IRF8, eliminating NOTCH2 dependence. This in turn leads to enhanced
expression of PAX5 and TLR9, a genetic profile associated with mature follicular B cells
capable of producing protective Ab against bacteria and viruses, as well as to vaccines.
Importantly, these B cells attain functional memory essential for long-term humoral
immunity.
and 7B), consistent with findings by others in healthy and common
variable immunodeficiency humanB cells.49,52ATRAenhancesB-cell
maturation from lymphoid progenitors in vitro and expands splenic
B cells in mice after vaccination.52,65 Agents that enable entry into
B-cellmaturation pathwaysmay eliminate autoreactiveB cells, in favor
of mature follicular B cells functional against pathogens. Retinoids
have been used clinically in human disease, both for treating acute
promyelocytic leukemia and for augmenting immunity.66,67 In a
limited case series, etretinate, a retinoid used in psoriasis, showed
some efficacy in sclerodermatous cGVHD.68 Likewise, the ATRA-
like retinoid Am80 reduced cutaneous cGVHD in a mouse model,69
potentially through modulation of effector T cells, although a pos-
sible role for B cells was also acknowledged, but not examined.
Collectively, our findings now suggest that retinoids and similar
agents that modulate immune cell function warrant further study in
cGVHD.
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stimulation (Figure 1D-E), providing evidence that a NOTCH2-
BCR axis operates from the most proximal steps of BCR signaling. 
NOTCH2 may play a role in how cGVHD B cells are primed to 
respond to alloantigens because anti-N2 blocked active cGVHD B-
cell hyperresponsiveness (Figure 2A). In the face of this 
inappropriate activation signaling, cGVHD B cells appear unable 
to mature normally. Our findings may partially explain humoral 
immune dysregulation and profound immunodeficiency common 
in cGVHD.58
NOTCH2 blockade of active cGVHD B cells also led to the 
downregulation of genes associated with MZ B cells (Tables 2-3), 
including CR2/CD2159 and FCRL4/IRTA1,60 supporting our hypoth-
esis that circulating B cells in cGVHD patients share characteristics 
with MZ-like B cells. The glycosyltransferase MFNG (MANIC 
FRINGE), important for MZ-like B-cell promotion by NOTCH2,41 
was significantly reduced following NOTCH2 blockade (Figure 2C; 
Table 4). NOTCH2 blockade was not coincident with complete 
abrogation of cell-activation pathways. FOS was among the genes 
upregulated in cGVHD B cells after NOTCH2 blockade (Tables 2-3), 
supporting the previously published role for FOS in suppressing 
BCR-mediated proliferation,61 and this accompanied an overall en-
hancement of the MAPK-signaling pathway (supplemental Figure 1B; 
supplemental Table 3). FOS can participate in BLIMP1 expression and 
antibody-secreting cell (ASC) differentiation.62 However, ASCs were 
not generated following NOTCH2 blockade of cGVHD B cells, and 
BLIMP1 expression was not significantly altered (RNA-Seq; P 5 .2). 
These findings are consistent with anti-N2 attenuating hyperactivation, 
poising cGVHD B cells for receipt of additional signals needed for 
ASC differentiation.62
Consistent with findings by others, NOTCH2 expression is 
only detectable at modest levels on the B-cell surface.42 Low-
level NOTCH2 expression and posttranslational modifications of 
its extracellular domain by FRINGE glycosyltransferases41 are 
known to be sufficient for potent downstream NOTCH signaling 
and the development of autoreactive-prone MZ B cells.41,42 
We also reveal a positive feedback loop underpinning NOTCH2 
expression and activation. BCR activation in cGVHD associated 
with low levels of the transcription factor IRF4 and increased 
NOTCH2 cell-surface expression. IRF4 is known to be required 
for MZ B-cell formation by NOTCH2.28,29 Strikingly, with NOTCH-
BCR stimulation, NOTCH2 expression was maintained on cGVHD 
B cells, and ATRA treatment blocked this effect (Figure 6C). This 
suggests that targeting NOTCH2 as B cells encounter alloantigen 
and NOTCH ligand may be possible.
We found that reduced IRF4 associated with a relative increase in 
IRF8 in active cGVHD B cells stimulated with surrogate antigen 
(Figure 4). This is an important finding because BCR signaling is a 
primary driver of changes in IRF4 and IRF8 expression during B-cell 
development and activation, and a strict balance between IRF4 and 
IRF8 controls the emergence of major B-cell subsets in the peripheral 
B-cell pool.44,48,63 In conjunction with IRF4, IRF8 is also a crucial 
mediator of B-cell tolerance.45,64 These findings suggest that intrinsic 
transcription factor defects occur in surviving and potentially autoreactive 
B cells after HCT (Figure 7A), and that ATRA may normalize B-cell 
function (Figure 7B).
The B-cell maturation defect we have uncovered in cGVHD 
patients may lend itself to therapeutic intervention. ATRA induced a 
maturation program in cGVHD B cells that included increased IRF4, 
TLR9, and PAX5 expression and enhanced CpG responses (Figures 5
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